Recordkeeping CGMP for Medical Gases, Containers, and Closures

Current Good Manufacturing Practices for Finished Pharmaceuticals and Medical Gases

GFI for Medical Gases CDER draft

Recordkeeping CGMP for Medical Gases, Containers, and Closures

OMB: 0910-0139

⚠️ Notice: This form may be outdated. More recent filings and information on OMB 0910-0139 can be found here:

Document [pdf]

Download: pdf | pdf

Current Good
Manufacturing Practice
for Medical Gases
Guidance for Industry
DRAFT GUIDANCE
This guidance document is being distributed for comment purposes only.
Comments and suggestions regarding this draft document should be submitted within 60 days of
publication in the Federal Register of the notice announcing the availability of the draft
guidance. Submit electronic comments to https://www.regulations.gov. Submit written
comments to the Division of Dockets Management (HFA-305), Food and Drug Administration,
5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the
docket number listed in the notice of availability that publishes in the Federal Register.
For questions regarding this draft document, contact (CDER) Frank Perrella 301-796-3265.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
June 2017
Pharmaceutical Quality/Manufacturing Standards (CGMP)
Revision 1

Current Good
Manufacturing Practice
for Medical Gases
Guidance for Industry
Additional copies are available from:
Office of Communications, Division of Drug Information
Center for Drug Evaluation and Research
Food and Drug Administration
10001 New Hampshire Ave., Hillandale Bldg., 4th Floor
Silver Spring, MD 20993-0002
Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353
Email: druginfo@fda.hhs.gov
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)
June 2017
Pharmaceutical Quality/Manufacturing Standards (CGMP)
Revision 1

Contains Nonbinding Recommendations
Draft — Not for Implementation

TABLE OF CONTENTS
I.

INTRODUCTION............................................................................................................. 1

II.

STATUTORY AND REGULATORY REQUIREMENTS .......................................... 2

III.

ORGANIZATION AND PERSONNEL ......................................................................... 3

Quality Unit .................................................................................................................................... 3

1. Responsibilities ................................................................................................................................ 3
2. Quality Agreements With Suppliers ................................................................................................. 4
3. Supplier Qualifications .................................................................................................................... 4
B. Personnel Qualifications................................................................................................................ 4

IV.

BUILDINGS AND FACILITIES .................................................................................... 5

EQUIPMENT .................................................................................................................... 5
A.

Filling Equipment Qualification ................................................................................................... 5

Equipment Cleaning and Maintenance........................................................................................ 6

Equipment Calibration.................................................................................................................. 6

Computerized Systems .................................................................................................................. 7

VI.

COMPONENTS, CONTAINERS, AND CONTAINER CLOSURE SYSTEMS ....... 8

Components .................................................................................................................................... 8

Containers and Container Closure Systems ................................................................................ 8

1. General ............................................................................................................................................ 8
2. Prefill Inspections ............................................................................................................................ 9
C. Stock Rotation .............................................................................................................................. 12

VII.

PRODUCTION AND PROCESS CONTROLS........................................................... 12

Sampling and Testing .................................................................................................................. 12

Vacuum Evacuation of High-Pressure Cylinders ..................................................................... 12

Filling Procedure Checks ............................................................................................................ 13

1. Temperature and Pressure Readings ............................................................................................. 13
2. Valve Assembly Leak Testing ......................................................................................................... 13
3. Heat-of-Compression Check .......................................................................................................... 14
D. Calculation of Yield ..................................................................................................................... 14

VIII. PACKAGING AND LABELING CONTROLS .......................................................... 14
A.

Materials Examination and Usage ............................................................................................. 14

Labeling Control .......................................................................................................................... 14

Packaging and Labeling Operations .......................................................................................... 15

Expiration Dating ........................................................................................................................ 16

Contains Nonbinding Recommendations
Draft — Not for Implementation

IX.

HOLDING AND DISTRIBUTION ............................................................................... 16

LABORATORY CONTROLS ...................................................................................... 16
A.

General Requirements and Recommendations ......................................................................... 16

Calibration of Instruments.......................................................................................................... 17

Medical Gas Sampling and Testing ............................................................................................ 17
1.
2.
3.
4.

Cylinders Filled on a Multiple-Outlet Manifold ............................................................................ 18
Cylinders Filled Individually ......................................................................................................... 18
Mixtures ......................................................................................................................................... 18
Medical Gas From Suppliers ......................................................................................................... 18
Test Method and Alternative Test Method Validation............................................................. 19

Stability Testing ........................................................................................................................... 19

Reserve Samples ........................................................................................................................... 20

XI.

RECORDS AND REPORTS ......................................................................................... 20

General Requirements and Recommendations ......................................................................... 20
1.
2.
3.
4.
5.

Record Retention............................................................................................................................ 20
Record Review ............................................................................................................................... 20
Equipment Calibration, Checks, and Inspections .......................................................................... 20
Computer Validation Data............................................................................................................. 21
Process Validation Data ................................................................................................................ 21
Equipment Cleaning and Use Logs ............................................................................................ 21

Component, Container, Container Closure System, and Labeling Records .......................... 22

Master Production and Control Records................................................................................... 22

Batch Production and Control Records ..................................................................................... 23

Production Record Review and Investigations Records........................................................... 24

Laboratory Records ..................................................................................................................... 25

Distribution Records.................................................................................................................... 26

Complaint Files ............................................................................................................................ 26

Certificate of Analysis.................................................................................................................. 27

XII.

RETURNED MEDICAL GAS....................................................................................... 27

XIII. ADAPTERS ..................................................................................................................... 27
XIV. GLOSSARY..................................................................................................................... 27

Contains Nonbinding Recommendations
Draft — Not for Implementation

Current Good Manufacturing Practice for Medical Gases
Guidance for Industry 1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

This draft guidance, when finalized, will represent the current thinking of the Food and Drug
Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not
binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the
applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible
for this guidance as listed on the title page.

INTRODUCTION

This guidance is intended to assist manufacturers of medical gases in complying with applicable
current good manufacturing practice (CGMP) regulations (21 CFR parts 210 and 211). 2 Medical
gases are generally regulated as finished pharmaceuticals and are subject to CGMP requirements
regardless of the processing stage. Compliance with applicable CGMP requirements helps to
ensure the safety, identity, strength, quality, and purity of medical gases. Medical gases that are
not manufactured, processed, packed, or held according to applicable CGMP requirements can
cause serious injury or death. 3
Pursuant to its review of Federal drug regulations under the Food and Drug Administration
Safety and Innovation Act (FDASIA), 4 FDA determined, in part, that additional guidance
regarding the application of certain regulations to medical gases would be useful. 5 This
document provides such additional guidance regarding CGMP regulations. This guidance is
expected to reduce the regulatory compliance burden for the medical gas industry by providing
1

This guidance has been prepared by the Office of Pharmaceutical Quality and the Office of Compliance in the
Center for Drug Evaluation and Research in cooperation with the Office of Regulatory Affairs at the Food and Drug
Administration.
2
In this guidance, the term manufacturer includes any person or firm that manufactures a medical gas, which
includes producing, cascading, distributing, filling, mixing, purifying, separating, transferring, and transfilling
medical gases. See section XIV, Glossary, for definitions of different types of manufacturers.
3
A number of injuries and deaths have resulted from medical gases not being produced or handled properly. For
example, there have been a number of incidents in which a medical gas container holding a gas other than oxygen
was erroneously connected to a health care facility’s oxygen supply system. For further details regarding several of
these incidents, see proposed rule “Medical Gas Containers and Closures; Current Good Manufacturing Practice
Requirements” (71 FR 18039, April 10, 2006).
4

Public Law 112-144, 126 Stat. 993 (July 9, 2012); see section 1112(a)(2).

See FDA, 2015, Report to Congress: Review of Federal Drug Regulations With Regard to Medical Gases,
available at
http://www.fda.gov/downloads/RegulatoryInformation/Legislation/SignificantAmendmentstotheFDCAct/FDASIA/
UCM453727.pdf.

Contains Nonbinding Recommendations
Draft — Not for Implementation

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66

clear, up-to-date, detailed recommendations regarding CGMP issues that have been the subject
of industry questions.
This guidance supersedes the draft guidance for industry Current Good Manufacturing Practice
for Medical Gases issued in May 2003. 6
In general, FDA’s guidance documents do not establish legally enforceable responsibilities.
Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only
as recommendations, unless specific regulatory or statutory requirements are cited. The use of
the word should in Agency guidances means that something is suggested or recommended, but
not required.
II.

STATUTORY AND REGULATORY REQUIREMENTS

This guidance applies to medical gases that meet the definition of a drug under section 201(g)(1)
of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 7 including those that are recognized
in the United States Pharmacopeia-National Formulary (USP-NF). Gases that do not meet the
definition of a drug, including gases intended for industrial applications or nondrug medical
applications (e.g., a calibration gas used as a standard), are outside the scope of this guidance.
Medical gases—including those that are marketed pursuant to a new drug application (NDA)
submitted under section 505 of the FD&C Act or the certification process described in section
576 of the FD&C Act 8—are generally considered finished drug products.
A medical gas that meets the definition of a drug (referred to in this guidance as simply a
medical gas) is deemed to be adulterated under section 501(a)(2)(B) of the FD&C Act if “the
methods used in, or the facilities or controls used for, its manufacture, processing, packing, or
holding do not conform to or are not operated or administered in conformity with current good
manufacturing practice.” 9 Section 501 of the FD&C Act states that “the term current good
manufacturing practice includes the implementation of oversight and controls over the
manufacture of drugs to ensure quality, including managing the risk of and establishing the
safety of raw materials, materials used in the manufacturing of drugs, and finished drug
products.”
Medical gases that are subject to applicable CGMP requirements at 21 CFR parts 210 and 211,
and manufacturers of such medical gases, must meet these requirements to comply with section
501(a)(2)(B) of the FD&C Act (see 21 CFR 210.1(b)). Manufacturers that solely produce gases
for industrial or nondrug medical applications are not subject to these CGMP requirements.

See 68 FR 24005 (May 6, 2003).
See 21 U.S.C. 321(g)(1) for the definition of drug under the FD&C Act. See 21 U.S.C. 360ddd(2) for the definition
of medical gas and 21 U.S.C. 360ddd(a) for the definition of designated medical gas.
8
21 U.S.C. 360ddd-1.
9
21 U.S.C. 351(a)(2)(B).
7

Contains Nonbinding Recommendations
Draft — Not for Implementation

67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103

Manufacturers of medical gases need only comply with those CGMP requirements applicable to
the operations in which they are engaged (see § 210.2(b)).
III.

ORGANIZATION AND PERSONNEL
A.

Quality Unit

The establishment of an effective quality system reflects the principle that quality should be built
into the product; testing alone cannot ensure product quality. 21 CFR 211.22 provides that the
quality control unit (hereinafter quality unit) has the authority needed to create, monitor, and
implement a quality system. 10 The quality unit’s responsibilities and procedures must be in
writing and its procedures must be followed (§ 211.22(d)).
Manufacturers must have a quality unit with the responsibility and authority to approve or reject
all components, drug product containers, closures, in-process materials, packaging material,
labeling, and drug products and the authority to review production records to ensure that no
errors have occurred or, if errors have occurred, that they have been fully investigated. The
quality unit is also responsible for approving or rejecting drug products manufactured, processed,
packed, or held under contract by another company (§ 211.22(a)).
1.

Responsibilities

A quality unit’s size and complexity can vary with the size of the operation. For example, a
manufacturer that fills only oxygen and has very few employees might only have one person as
the quality unit, whereas a larger manufacturer with several locations might have a corporate
quality unit responsible for multiple locations. Either arrangement can satisfy the requirements of
§ 211.22. Staff at each manufacturing facility must follow procedures and specifications that are
approved by the appropriate quality unit (§ 211.22(c)).
As described in FDA’s guidance on maintaining a quality system, 11 production personnel and the
quality unit typically remain independent. Some medical gas manufacturing sites, however, have
limited personnel, and the individuals assigned to the quality unit also perform production
functions. These individuals implement all the controls and review the results of manufacture to
ensure that product quality standards established by the manufacturer have been met, regardless
of their production functions or other roles. FDA considers this approach to comply with CGMP
requirements provided that each individual who performs quality unit functions is adequately
trained and experienced in all quality unit tasks assigned (§ 211.25). FDA recommends that all

For purposes of this guidance, the term quality unit is synonymous with the term quality control unit. For the
definition of quality control unit, see § 210.3(b)(15). We note that FDA also takes this approach in its guidance for
industry Contract Manufacturing Arrangements for Drugs: Quality Agreements. We update guidances periodically.
To make sure you have the most recent version of a guidance, check the FDA Drugs guidance Web page at
http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.

See the ICH guidance for industry Q10 Pharmaceutical Quality System and the guidance for industry Quality
Systems Approach to Pharmaceutical CGMP Regulations.

Contains Nonbinding Recommendations
Draft — Not for Implementation

104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139

individuals who are part of the quality unit be identified by function and title in written
procedures to ensure that the appropriate quality unit responsibilities are fulfilled. 12
2.

Quality Agreements With Suppliers

The quality unit’s procedures should call for written quality agreements with suppliers of goods
and services that clearly describe the goods or services to be provided, quality specifications, and
communication mechanisms between the contracting parties; this assists in ensuring drug quality
and safety. 13 Timely communication about process changes that could affect the composition of
the gas supplied or about changes in tank cleaning services, for example, can prevent
contamination. Therefore, FDA recommends that written quality agreements with suppliers
define CGMP responsibilities and the communication processes for reporting complaints and
changes that could be critical to drug quality.
3.

Supplier Qualifications

Written procedures should explain how manufacturers qualify and approve suppliers. 14
Manufacturers should determine supplier qualifications to ensure that quality standards are met
and that purchased gases, including feeder gases, have an accurate and complete certificate of
analysis (COA). If using a supplier’s COA, manufacturers must conduct at least one specific
identity test and establish the reliability of the supplier’s analyses through appropriate validation
of the supplier’s test results at appropriate intervals (see § 211.84(d)). Such periodic testing may
be performed by the manufacturer, a third party, or a contract-testing laboratory. Manufacturers
can begin the supplier qualification process, for example, by fully testing several batches and
examining the gas, containers, and closures provided. 15 Manufacturers should periodically verify
the qualification of approved suppliers by conducting audits (on-site or remote), analyzing trends
in the quality of received goods, testing, and evaluating the timeliness of supplier responses to
complaints.
B.

Personnel Qualifications

All personnel, including those working on the manufacturing floor or driving to customer sites to
distribute medical gas, must have the education, training, and experience necessary to perform
their assigned functions (§§ 211.25(a) and (b)). Inadequately trained personnel could
inadvertently fill the wrong gas into a storage tank or connect the wrong gas to a gas supply
system, which can result in serious injury or death. 16
12

For quality unit requirements, see § 211.22.
For more information on quality agreements, see the guidance for industry Contract Manufacturing Arrangements
for Drugs: Quality Agreements.
13

Designated medical gases must be certified (see sections 575 and 576 of the FD&C Act). For more information on
certification of designated medical gases, see the draft guidance for industry Certification Process for Designated
Medical Gases. When final, this guidance will represent FDA’s current thinking on this topic.

15
16

In this guidance, the terms batch and lot are interchangeable.
See footnote 3.

Contains Nonbinding Recommendations
Draft — Not for Implementation

140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182

Personnel, including drivers, who connect portable cryogenic containers to gas supply systems
must be trained appropriately in the specifics of those supply systems. Drivers who deliver
multiple gases (including multiple medical gases or both medical and industrial gases) must be
trained to accurately identify each gas and distinguish among them. Personnel must be trained in
CGMP requirements on a continuing basis and with sufficient frequency to provide assurance
that they remain familiar with the applicable requirements (§ 211.25(a)). FDA recommends that
CGMP training be provided annually and that manufacturers keep training records that include
time and attendance entries.
IV.

BUILDINGS AND FACILITIES

The standard industry practice of refilling labeled medical gas containers underscores the
importance of building and facility design as a control method for proper operation. For example,
because facilities reuse labeled medical gas containers, filled and unfilled cylinders with
identical labeling may only be distinguishable if they are quarantined in well-defined areas.
Buildings must have a sufficient number of adequately sized areas for organized sequential
operations, including well-defined areas for incoming medical gases, containers, manufacturing
equipment, rejected containers and container closure systems, filling, and quarantine, as well as
finished product that is ready for distribution (§§ 211.42, 211.89). Outdoor spaces and delivery
truck beds may be appropriate areas to conduct certain operations (e.g., storage and handling) for
medical gases in pressurized containers. For example, industrial and medical gases could be
separated physically in the warehouse or in the delivery truck. To separate these areas from other
spaces (§ 211.42(c)), manufacturers should use identifiers such as signage, floor demarcation, or
tagging.
V.

EQUIPMENT
A.

Filling Equipment Qualification

Automatic, mechanical, and electronic equipment, or other types of equipment, must be checked
according to a written program designed to ensure proper performance (§ 211.68(a)). Equipment
qualification helps ensure proper performance. FDA recommends the following:
•

Equipment should be qualified at the temperature and pressures used during filling.

•

Manifold valves should be qualified for use (e.g., appropriately designed to prevent mixups during medical gas filling operations and shown to prevent contamination of medical
gas).

•

Other valves that are critical to the prevention of drug contamination, such as check
valves used in filling systems, should be qualified for use.

Contains Nonbinding Recommendations
Draft — Not for Implementation

183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227

Equipment Cleaning and Maintenance

21 CFR § 211.67 requires that equipment be adequately cleaned and maintained. FDA
recommends that medical gas manufacturers:
•

Ensure that equipment used in the manufacture of medical gases (e.g., manifolds, pigtails,
valve assemblies, hoses, gauges) is cleaned before initial use and after exposure to a
contaminant (e.g., industrial gas impurities).

•

Tailor their equipment cleaning and maintenance procedures to match the type and
complexity of the particular operation, as appropriate.

Closed pressurized systems used for filling medical gases (e.g., manifolds) need not be cleaned
between batches, unless exposed to a contaminant. To prevent contamination (§ 211.80(b)),
manufacturers should ensure that open ends are appropriately covered (e.g., with physical caps).
Components and drug product containers and closures must at all times be handled and stored in
a manner to prevent contamination (§ 211.80(b)). Accordingly, high-pressure cylinders exposed
to the elements and hoses used to fill cryogenic containers must have caps or other protective
means to prevent contamination (§ 211.80(b)).
Valves that are critical to the prevention of drug contamination, such as manifold or check valves
used in supply systems, must be properly maintained (§ 211.67).
Industrial and medical gases can sometimes be filled at different times on the same manifold
rack. This practice is acceptable as long as processes and procedures are in place and followed to
prevent any possible contamination caused by backflow from the industrial cylinders into the
medical cylinders or from residual industrial gas in the manifold.
For reporting requirements and recommendations, see section XI.B, Equipment Cleaning and
Use Logs.
C.

Equipment Calibration

Manufacturers must establish an appropriate schedule or frequency for equipment calibration
(§ 211.68). This can be done using either the equipment manufacturer’s recommended
calibration schedule or a schedule based on the medical gas manufacturer’s own historical data.
Medical gas manufacturers can reference the equipment manufacturer’s instruction manual in
their written procedures if the manual is available for use on-site. Medical gas manufacturers that
use automated, mechanical, or electronic equipment such as computer systems must ensure these
systems are routinely calibrated, inspected, or checked according to a written program designed
to ensure proper performance (§ 211.68(a)).
FDA recommends that manufacturers:

Contains Nonbinding Recommendations
Draft — Not for Implementation

228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266

•

Check the performance of vacuum gauges daily to ensure that the needle on the gauge
returns to zero when there is no vacuum or pressure (above atmospheric pressure).

•

Calibrate vacuum and pressure gauges annually against an established standard (e.g., a
standard from the National Institute of Standards and Technology). Low-pressure gauges
and flow meters used in filling cryogenic home containers do not require calibration, but
manufacturers should ensure that they function properly for their intended use.

•

Calibrate thermometers according to the equipment manufacturer’s instructions at least
annually.

•

Calibrate handheld oxygen analyzers based on the equipment manufacturer’s instructions
or a schedule based on the gas manufacturer’s own historical data.

See section XI.A.3 for records requirements related to equipment calibration, checks, and
inspections.
D.

Computerized Systems

Computerized systems, including hardware and software, used in the manufacturing, processing,
and holding of medical gases must be validated for their intended use (e.g., §§ 211.63, 211.68(a)
and (b)). 17 The depth and scope of the validation depend on the complexity and significance of
the computerized system.
Automated filling systems must be validated to provide assurance that the filling is done properly
(§§ 211.68, 211.100).
Computerized or automated systems must have sufficient controls to prevent unauthorized access
or changes to master production control records or other records and to ensure records or data are
accurate (§ 211.68(b)). In addition, any change to a computerized or automated system should be
made according to approved procedures, and any changes should be documented. 18 A risk
assessment should be performed to determine the potential of the computerized system to affect
product quality, safety, and record integrity. Manufacturers can use an audit trail as part of these
systems to address risk.
For examples of the validation of medical gas air separation unit (ASU) automated and computer
controls, see the Compressed Gas Association’s Guideline for Validation of Air Separation Unit
and Cargo Tank Filling for Oxygen USP and Nitrogen NF (CGA P-8.2, 5th ed., 2013).

For more information about validation, see the guidance for industry Process Validation: General Principles and
Practices.
18
For FDA’s current thinking on the use of computerized systems for maintaining electronic records, see the
guidance for industry Part 11, Electronic Records; Electronic Signatures—Scope and Application.

Contains Nonbinding Recommendations
Draft — Not for Implementation

267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312

VI.

COMPONENTS, CONTAINERS, AND CONTAINER CLOSURE SYSTEMS
A.

Components

Manufacturers must control and assess the quality of components (i.e., any ingredient intended
for use in the manufacture of a drug product) as specified in §§ 211.80, 211.82, 211.84, and
211.110. Recommendations for control of incoming components include the following:
•

ASUs should assess the air quality when validating the manufacturing process to
determine when it should be reassessed and to determine which air quality conditions
could require additional testing.

•

Original manufacturers that use a feeder gas as their raw material should perform an
initial and periodic characterization of the feeder gas (e.g., fingerprinting) for any
impurities that could affect the finished product safety and quality. They should also
assess levels of impurities in the feeder gas to ensure that the manufacturing process is
capable of adequate purification (i.e., remains valid under normal processing conditions).
Furthermore, original manufacturers should maintain written agreements with suppliers
of feeder gas so that they are informed of any changes that suppliers make that might
affect the composition of the feeder gas. (See also section III.A.2, Quality Agreements
With Suppliers.)
B.

Containers and Container Closure Systems

General

The quality unit must examine, reexamine as appropriate, and approve or reject containers and
container closure systems (§§ 211.22, 211.84, 211.87). A manufacturer should reexamine a
container or container closure system when, for example, it is stored for an extended period or
exposed to adverse environmental conditions. Rejected containers and container closure systems
must be identified and quarantined (§ 211.89). After customers use containers and container
closure systems and send them back for refilling, manufacturers must store them under
quarantine until they have been tested or examined, as appropriate (§ 211.82(b)).
Containers and container closure systems must be clean and must not be reactive, additive, or
absorptive so as to alter the safety, identity, strength, quality, or purity of a medical gas beyond
the official or established requirements (§ 211.94(a) and (c)). Thus, containers and container
closure systems should be cleaned before initial use and after exposure to a contaminant. In
addition, if converting a container’s use from industrial grade gas to medical gas, or if there is
reason to believe there was previous industrial use, manufacturers must implement appropriate
cleaning and retesting procedures (§§ 211.84, 211.94(c)).
Portable cryogenic containers that are not manufactured with permanent gas-specific use outlet
connections (e.g., those that have been silver-brazed) must have gas-specific use outlet
connections that are attached to the valve body so that they cannot be readily removed or
replaced (without making the valve inoperable and preventing the container’s use) except by the
8

Contains Nonbinding Recommendations
Draft — Not for Implementation

313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359

manufacturer (§ 211.94(e)(1)). If the gas-specific use outlet connection can be readily removed
and replaced, a container holding a gas other than oxygen could be inadvertently connected to an
oxygen supply system, causing serious injury or death.
Manufacturers should not use vapor recovery systems during carbon dioxide delivery. It is
possible that toxic contaminants or impurities present in the gaseous head space of the storage
tank or container could be drawn into the tank or container, thereby contaminating the carbon
dioxide.
2.

Prefill Inspections

Manufacturers should conduct prefill inspections to provide assurance that containers and
container closure systems are acceptable for use before filling begins. This section addresses
prefill inspections that evaluate containers and container closure systems used to hold incoming
medical gases and store medical gases and finished product containers and container closure
systems. Any prefill inspections performed must be properly documented (§ 211.184(b)).
Containers and container closure systems that fail prefill inspections must be quarantined until
the container, container closure system, or valve has been repaired, cleaned, or replaced, as
appropriate, and determined to pass reinspection (§§ 211.84, 211.89).
a.

External inspection

Container

Manufacturers should carefully examine each container for dents, burns, dings, oil, grease, and
other signs of damage or contamination that can cause a container to be unsafe for use. Any
container found to have any of these conditions must be quarantined until its suitability has been
determined (§§ 211.82, 211.84, 211.89).
ii.

Valves, inlets, outlets, and connectors

Manufacturers should carefully inspect each container’s valve assembly, connectors, and fittings
to ensure that they are appropriate for the medical gas. The valves, inlets, outlets, gauges, and
connectors should be examined carefully for signs of damage (including fire damage), unusual
wear, corrosion, or the presence of debris, oil, or grease. This inspection should cover any
connections that are brazed, welded, or equipped with a locking device.
b.

Label inspection

Manufacturers should examine the labeling on each container for legibility and accuracy and
should remove and replace damaged labels. Product labels on medical gas containers can be
reused. Labels that are obsolete or outdated must be removed (§ 211.122(e)).
Each portable cryogenic container must be conspicuously marked with a 360° wraparound label
identifying its contents (§ 201.328(a)(1)). The wraparound label must be placed on the sidewall
of the container as close to the top portion of the container as possible, but below the top weld
seam (§ 201.328(a)(1)(iv)). The name of the gas must be printed continuously around the 360°
9

Contains Nonbinding Recommendations
Draft — Not for Implementation

360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388

wraparound label so that it can be read around the entire container (e.g., Oxygen USP, Oxygen
USP, Oxygen USP) (§ 201.328(a)(1)(iii)), and the lettering for the name of the gas on the label
must be at least 2 inches high (§201.328(a)(1)(ii)). For containers that hold a single gas, either
the lettering or the label’s background must be in the appropriate color (e.g., green for oxygen)
with contrasting background or lettering (e.g., lettering in the designated color against a white
background, or white lettering on a background of the designated color) (§ 201.328(a)(1)(i)). 19
The 360° wraparound label or a separate label on the portable cryogenic medical gas container
must include, in conspicuous lettering, the phrase For Medical Use, Medical Gas, or some
similar phrase that indicates the gas is for medical use (§ 201.328(a)(2)).
The 360° wraparound label and, if separate, the For Medical Use label required for portable
cryogenic medical gas containers must be affixed to the container in a manner that does not
interfere with other labeling and such that it is not susceptible to becoming worn or inadvertently
detached during normal use (§ 211.94(e)(2)). Each label, as well as materials used for coloring
medical gas containers, must be reasonably resistant to fading, durable when exposed to
atmospheric conditions, and not readily soluble in water (§ 211.94(e)(2)).
Although permanently mounted cryogenic containers are not required to have a 360° label, such
containers should include content labeling that is easily readable from all sides.
c.

Color code inspection

The shoulder of each high-pressure medical gas cylinder must be colored in the color or colors
that correspond to the gas held in the cylinder; furthermore, the shoulder’s color or colors must
be visible when viewed from the top of the cylinder (§ 201.328(b)). The FDA-designated colors
identifying medical gases in high-pressure medical gas containers and portable cryogenic
medical gas containers are (§ 201.328(c)):
Medical Gas
Medical Air
Carbon Dioxide
Helium
Nitrogen
Nitrous Oxide
Oxygen
Mixture or Blend*

389
390
391

Color
Yellow
Gray
Brown
Black
Blue
Green
Colors corresponding to each component gas**

* The terms mixture and blend refer to combinations of medical gases.
**For example, green and gray for a blend of oxygen and carbon dioxide.

There are no specific color requirements for the 360° wraparound label for portable cryogenic medical gas
containers containing a mixture of gases. As stated above, however, there are requirements addressing the color of
the cryogenic container itself.

Contains Nonbinding Recommendations
Draft — Not for Implementation

392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437

Unlike high-pressure cylinders, portable cryogenic medical gas containers are not required to be
colored in whole or in part (see below for a discussion of the label requirements for portable
cryogenic medical gas containers). However, a portable cryogenic container may only be
colored, in whole or in part, in the FDA-designated colors in the chart above if the gas or gases
held in the container correspond to those colors (§ 201.328(a)(1)(v)). Alternatively, these
containers can be colored in a light-reflective color (e.g., white) that is not one of the FDAdesignated colors in the chart above.
Manufacturers should not rely solely or primarily on color coding to identify medical gases; the
label should be used as the primary means of identifying the product. Color coding provides an
additional safeguard to facilitate accurate identification and detection of potential errors.
d.

Prefill inspection of high-pressure cylinders

When inspecting high-pressure cylinders, manufacturers should conduct the following prefill
inspections (in addition to the previously mentioned prefill inspections).
i.

Inspection of high-pressure cylinders for the DOT requalification date

Manufacturers should examine each high-pressure cylinder for the U.S. Department of
Transportation (DOT) date stamped on the cylinder before use to verify that each cylinder
conforms with DOT requirements for requalification and marking of cylinders (see, e.g., 49 CFR
180.209). If the DOT requalification date has been exceeded, the cylinder should be quarantined
until either DOT requirements have been satisfied or the cylinder is removed from inventory.
ii.

Hammer or dead-ring test

Manufacturers should conduct a hammer or dead-ring test to provide information about internal
corrosion of steel cylinders. The test consists of lightly tapping the cylinder sidewall with a
hammer-like instrument. The hammer or dead-ring test should not be performed on aluminum or
composite cylinders because the test would not indicate internal corrosion and could damage the
cylinder wall.
iii.

Odor inspection

Manufacturers can use an odor test to detect the presence of any foreign gas or odor remaining in
the container. This test should not be performed on carbon dioxide, nitrous oxide, or toxic or
corrosive gases for safety reasons. This test should not be confused with finished product testing,
for which an odor test may be included in a USP-NF monograph.
If a cylinder is empty (at atmospheric pressure), manufacturers can introduce Nitrogen NF into
the cylinder at a predetermined pressure and perform an odor test on the resulting gas.
Residual pressure valves prevent the cylinder from emptying completely and also prevent
backflow. A prefill odor test on a cylinder with a qualified residual pressure valve is not
necessary if the cylinder has residual pressure. Manufacturers should document verification of
11

Contains Nonbinding Recommendations
Draft — Not for Implementation

438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479

residual pressure on the batch record. For batch records and reporting requirements and
recommendations, see section XI.E, Batch Production and Control Records.
iv.

Venting or blow down of cylinders

High-pressure cylinders that are received for refilling should be vented or blown down
appropriately to remove any gas remaining in the cylinders. Manufacturers can omit this step if
the cylinder is equipped with a qualified residual pressure valve and has residual pressure.
C.

Stock Rotation

Medical gas containers and container closure systems are typically reused over a period of years
and undergo prefill testing. Accordingly, FDA does not intend to object if medical gas
manufacturers do not comply with the containers and container closure systems requirements in
§ 211.86 for stock rotation and use of the oldest containers and container closure systems first.
Manufacturers should address the continued suitability of containers and container closure
systems after extended storage by having procedures in place to ensure that they (1) are not
exposed to conditions that may render them unfit for use, and (2) have undergone prefill tests.
VII.

PRODUCTION AND PROCESS CONTROLS
A.

Sampling and Testing

Control procedures must be established to monitor output and to validate the performance of
manufacturing processes that may cause variability in the quality of the medical gas (§ 211.110).
For example, to address variation in the quality of feeder gas or atmospheric air, original
manufacturers should validate the process to remove contaminants.
B.

Vacuum Evacuation of High-Pressure Cylinders

For those cylinders that are not equipped with a residual pressure valve with backflow
prevention, FDA recommends vacuum evacuation to remove residual gases when cylinders are
being reused. FDA recommends manufacturers use 25 or more inches of mercury vacuum for
high-pressure cylinders to vacuum evacuate the residual gases. If using less than 25 inches of
vacuum, manufacturers should have data on file demonstrating that the amount of vacuum
evacuation sufficiently removes all residual gases from high-pressure cylinders.
Manufacturers must maintain records of any problems that occur with container evacuation, such
as the inability to adequately empty the cylinder of residual gases (§§ 211.84, 211.184). Data
regarding changes to the amount of vacuum used must be available for inspection (§§ 211.84,
211.94, 211.100, 211.184), and such changes should be scientifically justified.

Contains Nonbinding Recommendations
Draft — Not for Implementation

480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518

Filling Procedure Checks

Components must be weighed or measured as appropriate (§ 211.101(b)). When filling highpressure cylinders, manufacturers should include the following checks to demonstrate the
presence of gas in the container and to ensure net content is delivered.
1.

Temperature and Pressure Readings

A medical gas in a high-pressure cylinder increases in pressure as the temperature of the gas
rises. Overfilled cylinders can reach dangerously high pressures if exposed to elevated
temperatures, even if the pressure at room temperature is safe. To ensure that high-pressure
cylinders are filled correctly (i.e., contents as indicated on the label), the manufacturer can attach
a thermometer to one cylinder per manifold-filling sequence, or to each cylinder if filling one at
a time, and adjust the final filling pressure according to a temperature/pressure chart.
Manufacturers should use temperature/pressure charts or temperature/pressure calculations
(Boyle’s Law) to adjust filling pressure, thereby achieving proper content. This is usually stated
as the pressure at 70°F with appropriate tolerances.
The manufacturer must record the actual temperature and/or pressure readings on the batch
production record (§ 211.188(b)). For batch records and reporting requirements and
recommendations, see section XI.E, Batch Production and Control Records.
2.

Valve Assembly Leak Testing

During filling operations, manufacturers should test each valve assembly for leaks by spraying or
brushing an appropriate leak detection solution on and around the entire assembly. 20 The solution
should be safe for use with oxygen, leave no residue that is flammable, and be noncorrosive to
the valve assembly. That is, it should not contain hydrocarbons, ammonia, ethylene glycol, or
halide ions. Solutions containing soap are not recommended because they can corrode the valve
stem and leave a residue. Manufacturers should perform this test while the cylinder is under
pressure with the cylinder valve open. If bubbles appear, there is a leak.
Once the cylinders are filled and disconnected, manufacturers should perform a second valve
assembly leak test. If any leaks are detected, the cylinder must be removed from service and
quarantined until repaired (§§ 211.82, 211.89).
Performing these two tests helps ensure that the contents of high-pressure cylinders will not leak
during storage or shipment.

See ASTM International, 2011, G188-05 (2011), Standard Specifications for Leak Detector Solutions Intended for
Use on Brasses and Other Copper Alloys.

Contains Nonbinding Recommendations
Draft — Not for Implementation

519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564

Heat-of-Compression Check

During or immediately after filling high-pressure cylinders, manufacturers should perform a
heat-of-compression check by lightly touching the exterior of each cylinder or by following an
alternative method that verifies temperature change. A warm cylinder indicates that the cylinder
is filling properly; a cool or cold cylinder indicates that the cylinder may not be filling properly.
Manufacturers should investigate cool or cold cylinders.
D.

Calculation of Yield

Medical gas loss is expected during manufacturing and can be variable even under normal
operating conditions. Accordingly, FDA does not intend to object if medical gas manufacturers
do not comply with the requirements in § 211.103 for calculation of actual yield and percentages
of theoretical yield. Filling to a predetermined and acceptable temperature or pressure limit,
along with finished product testing, is sufficient to determine that the medical gas or medical gas
mixture in the container is the amount and type indicated by the label and required by the final
product specifications (see §§ 211.134, 211.165).
VIII. PACKAGING AND LABELING CONTROLS
A.

Materials Examination and Usage

According to §§ 211.122(a), (d), and (e) and 211.125(b), manufacturers must:
•

Representatively sample new labels and other labeling materials and compare them for
accuracy to the master label before use in labeling of a medical gas.

•

Secure labeling by limiting access to authorized personnel.

•

Destroy obsolete and outdated labeling.

Different medical gas labels should be stored separately. They can be stored in the same cabinet
provided they are adequately separated to prevent mix-ups (see § 211.130). Industrial gas labels
should be stored in a separate area.
Only labeling that meets appropriate written specifications may be approved and released for use
(§ 211.122(b)). Previous lot numbers on any labeling must be removed or obliterated
(§ 211.67(b)(4)).
See section VI.B.2.c for more information about prefill label inspections.
B.

Labeling Control

Manufacturers must strictly control labeling issued for use in medical gas operations
(§ 211.125(a)). To prevent mix-ups, manufacturers should compare the number of labels issued
with the number of labels applied.
14

Contains Nonbinding Recommendations
Draft — Not for Implementation

565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605

For cut labeling that does not use a dedicated product labeling and packaging operation,
manufacturers must use appropriate electronic or electromechanical equipment or visual
inspection to conduct a 100-percent examination for correct labeling or any automated technique
that physically prevents incorrect labeling from being processed by labeling and packaging
equipment (§ 211.122(g)).
Label reconciliation is waived for 360° wraparound labels on portable cryogenic medical gas
containers (§ 211.125(c)).
FDA recommends that all labeling be issued for use in medical gas labeling operations by
authorized personnel only.
C.

Packaging and Labeling Operations

Manufacturers should consider as a batch each (1) manifold filling sequence, (2) uninterrupted
filling sequence, and (3) filled rail tank car, trailer, and cryogenic container. 21 For continuous
manufacturing operations (including ASUs), manufacturers should designate a batch as the
amount of medical gas produced in 24 hours or less. Each batch must be assigned a lot or control
number from which the history of the manufacture and control of the batch may be determined
(§§ 210.3(b)(11), 211.130(c)).
Transfillers receiving shipments of medical gas into a storage tank should assign a new lot
number to the contents of the storage tank each time it is refilled, regardless of whether it
contains previously received medical gas.
Manufacturers should ensure that for each container, the labeling accurately identifies the
contents of the container and that any other required or included information in labeling is
accurate. This is particularly important given that medical gas containers and labels are typically
reused many times. Labels should be affixed to the container in a manner that does not interfere
with other labeling and will not be susceptible to wear or inadvertent detachment during normal
use. For portable cryogenic container labeling requirements, see § 211.94(e)(2).
A separate sticker or decal may be used to identify the lot number for a batch of medical gas, as
long as the sticker remains adhered to the container and is legible. The sticker should be readily
visible and should not obscure required drug information. A separate sticker can also be used for
the container’s net content information.
For information about prefill label inspections, see section VI.B.2.c and for labeling records, see
sections XI.C and XI.E.

Under § 210.3, “batch means a specific quantity of a drug or other material that is intended to have uniform
character and quality, within specified limits and is produced according to a single manufacturing order during the
same cycle of manufacture.”

Contains Nonbinding Recommendations
Draft — Not for Implementation

606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651

Expiration Dating

Medical gases have unique stability characteristics. Accordingly, FDA does not intend to object
if manufacturers of designated medical gases do not comply with the expiration dating
requirements in § 211.137(a) for those gases (see also section X.E, Stability Testing). The
containers and closures should, however, be verified as capable of holding gas at the appropriate
pressure before release for distribution (see section VII). If a manufacturer labels a medical gas
with an expiration date, it must be supported by stability studies (§ 211.137(b)).
IX.

HOLDING AND DISTRIBUTION

Manufacturers must establish and follow written procedures describing medical gas distribution
(§ 211.150). These procedures must include a system by which the distribution of each batch can
be readily determined to facilitate its recall if necessary (§ 211.150(b)).
The procedures should explain (1) who would evaluate distribution information, (2) how a recall
would be initiated, (3) who would be informed about the recall, and (4) what would be done with
the recalled product.
Because of the nature of medical gas manufacturing and the stability characteristics of the gases,
FDA does not intend to object if medical gas manufacturers do not establish and follow written
procedures to distribute their oldest stock first (as required by § 211.150(a)), provided that
manufacturers establish a system to manage and handle medical gas stock in an orderly manner
and have procedures in place. These procedures should ensure that the components, containers,
and container closure systems (1) are used in a timely manner, (2) are not exposed to conditions
that may render them unfit for use, and (3) have undergone prefill and other testing as required
before distribution.
X.

LABORATORY CONTROLS
A.

General Requirements and Recommendations

Manufacturers must follow the laboratory control requirements in subpart I of part 211, follow
and document the laboratory controls at the time of performance, and record and justify any
deviations from the written specifications, standards, sampling plans, test procedures, and other
laboratory control mechanisms (§ 211.160(a)). For example, manufacturers must record and
justify changes made to the analytical method, such as a different column length or a different
carrier gas.
Designated medical gases that have been certified must meet the standards set forth in an
applicable compendium.
The manufacturing processes used for industrial grade gas could result in a gas with higher levels
of impurities than permitted in gas for medical use or impurities not specified in the relevant
USP-NF monograph. Accordingly, FDA does not recommend converting industrial grade gas to
medical gas. However, if a manufacturer chooses to convert industrial grade gas to medical gas,
16

Contains Nonbinding Recommendations
Draft — Not for Implementation

652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692

such conversion requires testing in addition to testing for conformance to the applicable USP-NF
monograph (see section VI.A, Components, for discussion of characterizing a feeder gas).
When the likelihood of contamination has been identified during prefill inspections or filling
operations, the manufacturer must quarantine the medical gas until an investigation has been
completed (§§ 211.84, 211.89, 211.110(d), 211.192). The medical gas may not be released
unless the investigation shows that the medical gas is not contaminated and that it meets product
specifications (§ 211.84). Manufacturers should use tests suitable for detecting such
contaminants as well as the tests provided in the approved application or USP-NF monograph. 22
B.

Calibration of Instruments

Laboratory controls must include a written program for calibration of instruments, apparatus,
gauges, and recording devices at suitable intervals (§ 211.160(b)(4)).
Manufacturers should verify that the calibration gas is traceable to a nationally recognized
standard and that it ensures the appropriate level of precision and accuracy. The COA for the
calibration gas should be specific to the cylinder of calibration gas received and should contain
the following:
•
•
•
•
•
•
•

Name and address of the supplier.
Name of the calibration gas.
Lot number or unique identification number.
Description of the analytical method used to assay the calibration gas.
Analytical results expressed quantitatively (e.g., 99.9 percent nitrogen).
Statement that the calibration gas is traceable to a nationally recognized standard.
Responsible person’s signature and the date signed.

See section V.C. for additional information about equipment calibration.
C.

Medical Gas Sampling and Testing

For each batch of medical gas, there must be an appropriate laboratory determination of
satisfactory conformance to final specifications for the medical gas, including testing for identity
and strength, before release (§ 211.165(a)). Written procedures must describe (1) sampling and
testing plans that include the number of units per batch that will be sampled and tested, (2) the
acceptance criteria for sampling and testing, and (3) actions to be taken if test results are outside
of specifications (§ 211.165).
FDA recommends that manufacturers document conformance to specification(s) in a COA for
each batch of medical gas filled. See section XI.J for more information about COAs. When test

Refer to USP-NF General Notices, Section 5.60, Impurities and Foreign Substances, available at
http://www.usp.org/usp-nf/development-process/policies-guidelines/usp-nf-general-notices.

Contains Nonbinding Recommendations
Draft — Not for Implementation

693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733

results do not meet specifications, retesting is not recommended until a thorough investigation
has been performed according to established written procedures. 23
1.

Cylinders Filled on a Multiple-Outlet Manifold

At least one high-pressure cylinder from each manifold filling sequence should be tested for
identity and strength.
2.

Cylinders Filled Individually

One high-pressure cylinder per uninterrupted filling sequence should be tested for identity and
strength.
3.

Mixtures

For mixtures containing two gases, each high-pressure cylinder should be tested for both the
identity and strength of one of the gases, and one cylinder from each batch should be tested for
the identity of the second gas.
For mixtures containing three gases, each high-pressure cylinder should be tested for both the
identity and strength of two of the gases, and one cylinder from each batch should be tested for
the identity of the third gas.
Note: For mixtures containing oxygen, each cylinder should be tested for the identity and
strength of the oxygen.
4.

Medical Gas From Suppliers

Manufacturers receiving a batch of medical gas from suppliers should test for conformance to
established specifications after receipt or before the manufactured lot is released (e.g., for further
processing or transfilling). This can be done either by sampling directly from the storage tank or
by testing one container from the first batch of medical product filled.
If manufacturers receive and maintain supplier COAs, the manufacturers must conduct specific
identity testing (§ 211.84(d)(2)) and should conduct purity testing. FDA does not intend to object
if Oxygen USP transfillers delivering to sites that only receive Oxygen USP do not conduct at
least one specific identity test, as long as they witness the identity testing that their oxygen
suppliers conduct. Employees who witness oxygen testing must have appropriate training
(§ 211.25) and should record that they have witnessed the testing and document the method used
and identity of the person who performed the test.

See the guidance for industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical
Production.

Contains Nonbinding Recommendations
Draft — Not for Implementation

734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775

Test Method and Alternative Test Method Validation

When a test is approved as part of an NDA or an abbreviated new drug application, it becomes
the approved analytical test method or manufacturing method for the medical gas.
Manufacturers must use approved analytical test methods for the medical gas they manufacture
(§ 211.22(d)). USP-NF monograph drug products must meet USP-NF monograph standards
(section 501(b) of the FD&C Act; 21 U.S.C. 351(b)), and manufacturers should use the test
methods in the appropriate USP-NF monograph. For USP-NF test methods, a full test method
validation study is unnecessary (§ 211.194). Data that verify that the USP-NF test method is
accurate and reliable should be generated on the appropriate equipment and maintained at the
manufacturing site. If a medical gas manufacturer relies on the equipment manufacturer’s study,
the medical gas manufacturer should retain a copy of the actual study, including the protocol and
data.
Manufacturers that use approved test methods that are not USP-NF monograph methods must
maintain a copy of the full and complete test method validation (§ 211.165).
For USP-NF monograph drug products, a manufacturer can establish alternative test methods, as
long as the USP-NF monograph standards are met or exceeded. Alternative test methods must be
validated (§§ 211.160(b), 211.165(e)). The validation can be performed in accordance with USPNF General Chapter <1225> Validation of Compendial Procedures, and the validation study
should include data comparing it to the official test method. 24
FDA recommends that methods be validated under the same conditions in which they will be
used. If the testing environment is considerably different, manufacturers should conduct
additional on-site tests, such as with a small number of standard gases, to demonstrate that
method performance has not been affected by local conditions. For example, paramagnetic
oxygen analyzers can give inaccurate readings when used at high altitudes unless special
adjustments are made. The results of these tests should be fully documented.
Certain changes made to instrumentation may be substantive enough to be considered changes to
the test method itself; these changes would require additional documentation of the accuracy and
reliability of the method or a new validation study (see § 211.194(b)).
E.

Stability Testing

If an expiration date is assigned to a batch, manufacturers must establish, document, and follow a
stability testing program (§§ 211.137, 211.166). If an expiration date is not assigned to a
designated medical gas, supporting stability studies are not needed (see section VIII.D,
Expiration Dating).

See the guidance for industry Analytical Procedures and Methods Validation for Drugs and Biologics.

Contains Nonbinding Recommendations
Draft — Not for Implementation

776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815

Reserve Samples

Per § 211.170, reserve samples for compressed medical gases need not be retained.
XI.

RECORDS AND REPORTS

Manufacturers must maintain a number of records, including but not limited to those described
by § 211.68 and subpart J of part 211. This section reviews some of these requirements and also
provides recommendations regarding records and reports.
A.

General Requirements and Recommendations

Record Retention

For products with an expiration date, any required production, control, or distribution record
must be retained for 1 year after the expiration date of the batch (§ 211.180(a)). If the batch of
medical gas is not labeled with an expiration date, the aforementioned records should be
maintained for at least 3 years after the batch distribution date. FDA also recommends that
manufacturers retain training records and COAs for at least 3 years.
All records required under part 211, or copies of such records, must be readily available for
authorized inspection during the retention period at the establishment where the activities
described in such records occurred (§ 211.180(c)). Records can be kept on paper or
electronically. 25
2.

Record Review

Manufacturers must review a representative number of batch records, complaint files,
investigations, recalls, and returned products annually to determine the need for changes in drug
product specifications for manufacturing or control procedures (§ 211.180(e)). In addition,
manufacturers should use these records to identify potential product quality issues and
opportunities for continuous process improvement. This can be done on a companywide or siteby-site basis.
3.

Equipment Calibration, Checks, and Inspections

Manufacturers must keep records of calibration, checks, and inspections of electronic equipment
used in the manufacture, processing, and holding of medical gas (§ 211.68(a)). See section V.C.
for more information about equipment calibration.

Electronic records are subject to the requirements of 21 CFR part 11 (see the guidance for industry Part 11,
Electronic Records; Electronic Signatures—Scope and Application).

Contains Nonbinding Recommendations
Draft — Not for Implementation

816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859

Computer Validation Data

Manufacturers (including ASUs) must have documentation that their automated, mechanical, and
electronic equipment—including computers used in the manufacturing or holding of a gas—
demonstrates proper performance (§ 211.68(a)).
5.

Process Validation Data

Manufacturers must have process validation records showing that their operational and process
control procedures ensure that medical gases have the identity, strength, quality, and purity that
they purport or are represented to possess (§ 211.100). (For more information on FDA
recommendations regarding process validation, see the guidance for industry Process Validation:
General Principles and Practices.)
B.

Equipment Cleaning and Use Logs

For medical gases that are manufactured using closed pressurized systems and equipment, the
system and equipment generally does not need to be cleaned between batches, unless exposed to
a contaminant. See section V.B, Equipment Cleaning and Maintenance.
Manufacturers should retain records of cleaning pressurized systems and equipment before
commissioning for production use.
When cleaning or maintenance is required, manufacturers should document the work on separate
cleaning or maintenance records that are not associated with specific batch records. The people
who perform cleaning and maintenance and those who verify it must date and sign or initial the
log indicating that the work was performed (§ 211.182). If automated equipment is used in
cleaning and maintenance in accordance with § 211.68(c), only the person verifying the cleaning
and maintenance needs to date and sign or initial the log.
If using equipment dedicated to a single medical gas, manufacturers may keep control records
for cleaning, maintaining, and using the equipment as a part of the batch records, provided that
batches of the medical gas follow in numerical order and are manufactured in numerical
sequence (§ 211.182).
Equipment logs, including maintenance records, are critical for original manufacturers (including
ASUs) because of the complex nature of the manufacturing equipment and associated
maintenance requirements (e.g., carbon beds, dryer beds, distillation units).
Manufacturers should maintain cleaning and use logs for their filling equipment used on- or offsite.
See also section V.B. Equipment Cleaning and Maintenance.

Contains Nonbinding Recommendations
Draft — Not for Implementation

860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903

Component, Container, Container Closure System, and Labeling Records

Records must include the following (§ 211.184):
•

The identity and quantity of each shipment or each batch of newly purchased
components, containers, or container closure systems. The records must contain the
supplier’s name, lot number if known, and date of receipt. Manufacturers should also
maintain records of the serial numbers of newly purchased containers or container closure
systems. Original manufacturers (including ASUs) that use a feeder gas or atmospheric
air as a component should maintain records of the periodic testing they conduct. (See
section VI.A for testing recommendations.)

•

The results of any test or examination performed on components, containers, and
container closure systems. (See section VI for testing requirements and
recommendations.)

•

Documentation of the examination of labels and labeling for conformity with established
specifications. (See section VIII for labeling requirements and recommendations.)

•

The disposition of rejected medical gas components, containers, container closure
systems, and labeling.

Medical gas loss is expected during storage and manufacturing, and medical gas is subject to
release testing (see section X.C, Medical Gas Sampling and Testing). Therefore, because of the
expected loss, FDA does not intend to object if the requirement at § 211.184(c) regarding
reconciliation of individual inventory records is not met with respect to medical gases that are
components of the finished drug product.
Quality agreement records should be maintained with the other required records and available for
FDA review. See section III.A.2 for more information about quality agreements.
D.

Master Production and Control Records

Master production and control records are necessary to ensure uniformity from batch to batch.
These required records must be prepared, dated, and signed by one person and independently
checked, dated, and signed by a second person (§ 211.186(a)). These records must include
(§§ 211.186(a) and (b)):
•

A description of the medical gas containers, container closure systems, and packaging
materials, including a specimen or copy (e.g., electronic copy) of each label and labeling.

•

Complete manufacturing and control instructions, sampling and testing procedures,
specifications, special notations, and precautions to be followed.

Contains Nonbinding Recommendations
Draft — Not for Implementation

904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949

Batch Production and Control Records

Batch production and control records must be prepared for each batch of medical gas produced
and must include complete information related to the production and control of each batch
(§ 211.188). These records must include but are not limited to:
•

A reproduction of the appropriate master production or control record, checked for
accuracy, dated, and signed.

•

Documentation that each significant step in batch manufacture, processing, packing, or
holding was accomplished, including:
o Date of performance.
o Lot number or other unique identification number.
o In-process and batch test results.
o Description of medical gas containers and container closure systems.
o Any sampling performed.
o Identification of the people performing and directly supervising or checking each
significant step.
o Any investigation made according to § 211.192.
o Results of examinations made according to § 211.134.

Batch production records must clearly and accurately reflect actual production practices and
conditions at the time of manufacture (§ 211.188). Transfiller pumper’s or filler’s logs can be
used as batch production records if they contain all relevant information as specified in
§ 211.188 and in section XI.D, Master Production and Control Records.
In addition to the requirements listed above, FDA recommends that batch records maintained by
transfillers, including curbside vendors, also document:
•
•
•
•
•

Prefill inspections.
Number and size of the cylinders or cryogenic containers filled.
Filling inspections.
Postfill inspections.
Final temperature and pressure results or other inspection results.

Manufacturers need not store and maintain batch production records as one document; however,
all the required batch record information should be easily located and traceable to each specific
batch manufactured. Continuous processing logs can designate lot numbers and entries (e.g.,
23

Contains Nonbinding Recommendations
Draft — Not for Implementation

950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993

initials, dates) demonstrating that each significant step in the operation has been checked.
Manufacturers that use computer-controlled equipment during manufacture should establish and
follow procedures to maintain, review, and approve the manufacturing data.
Manufacturers must not use a single entry to indicate that all of the significant manufacturing,
processing, packing, and holding steps have been performed (§ 211.188(b)). A checkmark or
other symbol should not be used in place of an actual value, such as for temperature and pressure
readings, purity, and identity results.
FDA recommends that manufacturing records identifying nonconforming medical gas describe
the rejection relative to the rest of the batch to ensure that the scope of the investigation is
appropriate. Medical gases rejected for container leaks and medical gases rejected for manifold
leaks during filling must be documented (§§ 211.165, 211.188) and investigated (§ 211.192).
The scope of the investigation into a manifold leak must extend to other batches of medical gas
that may have been associated with the same failure (§ 211.192).
Complete labeling control records, including specimens or copies of all labels used, and
examination results must be included in the batch record (§ 211.188(b)(8)). A photocopy or
printed digital image can be an appropriate alternative to a label specimen. A specimen of the
specific lot number labeling (e.g., lot number sticker) should also be included in the batch record.
Labeling control records maintained by original manufacturers (including ASUs) that fill bulk
trailers may or may not include a finished product label; however, these manufacturers should
maintain both product and lot-specific labeling.
Each lot number should be traceable in records for batch manufacturing, labeling, testing, and
release.
F.

Production Record Review and Investigations Records

The quality unit must review and approve all medical gas production and control records,
including those for packaging and labeling, before a batch is released or distributed (§ 211.192).
Unexplained discrepancies or the failure of a batch to meet its specifications, including any test
results outside of established limits, must be thoroughly investigated, whether or not the batch
has already been distributed (§ 211.192). Manufacturers must maintain records of investigations,
which must include conclusions and follow-up information (§§ 211.180, 211.192).
For original manufacturers (including ASUs):
•

FDA recommends that third-party consignees (e.g., trucking company staff) not perform
the quality unit release of a medical gas.

•

If filling occurs when the quality unit is not on site, the quality unit is responsible for
review and approval before distribution (§ 211.192).

Contains Nonbinding Recommendations
Draft — Not for Implementation

994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039

For curbside vendors of oxygen, the quality unit must review documentation associated with the
off-site filling operation, including records of all inspections and maintenance procedures
performed (§ 211.22(a)).
G.

Laboratory Records

Laboratory records must include complete data derived from all tests necessary to ensure
compliance with established specifications and standards, including examinations and assays
(§ 211.194). These records include the following:
•

Description of the sample, lot number, location from which the sample was obtained, date
the sample was taken, and date received for testing.

•

Statement of each method used to test the sample.

•

Complete record of all data created in the course of each test—including graphs, charts,
and spectra from laboratory instrumentation—properly identified to show the specific
medical gas and the batch tested. If the analytical equipment only provides a direct
reading, visual observation and subsequent recording of the specific result for each test
would fulfill the data requirements.

•

Record of all calculations performed in connection with the test, including units of
measure, conversion factors, and equivalency factors.

•

Statement of the test results and how the results compare with established standards of
identity, strength, quality, and purity for the component (e.g., feeder gas), in-process
materials (as applicable), and finished product (see section XI.J, Certificate of Analysis).

•

Initials or signature of the person who performs each test and the dates the tests were
performed.

•

Initials or signature of a second person showing that the original records have been
reviewed for accuracy, completeness, and compliance with established standards.

In addition, manufacturers must maintain complete records of:
•

Any modification of an established method employed in testing, including justification.

•

Any testing and standardization of laboratory reference standards, reagents, and standard
solutions (e.g., a reference gas or calibration gas used as a standard).

•

The periodic calibration of laboratory instruments, apparatus, gauges, and recording
devices required by § 211.160(b)(4).

When testing is done by a chromatographic method specified in the USP-NF (e.g., the assay
method for Nitrogen NF), the chromatographic system must meet all system suitability
25

Contains Nonbinding Recommendations
Draft — Not for Implementation

1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081

requirements listed in the monograph (see section 501(b) of the FD&C Act). If the USP-NF
monograph lacks specific suitability requirements, manufacturers should use USP-NF General
Chapter <621> Chromatography as a reference.
H.

Distribution Records

Distribution records must contain the product name and strength, dosage form description,
consignee’s name and address, shipping date, and quantity shipped (§ 211.196). For medical
gases, distribution records do not need to contain lot numbers. Instead, manufacturers can use the
name of the medical gas, consignee’s name and address, shipping date, and quantity shipped to
comply.
Record maintenance according to written procedures is critical for batch traceability, particularly
during a product recall. See section IX of this guidance and § 211.150 for more information.
I.

Complaint Files

Manufacturers must maintain written records of each complaint in a file designated for medical
gas complaints (§ 211.198(b)). Manufacturer complaint records must include, if known
(§§ 211.198(a) and (b)):
•

Medical gas name and lot number.

•

Complainant’s name and contact information (and, if appropriate, title).

•

Full description of the nature of the complaint. 26

•

Any evaluation to determine if the complaint is also an adverse event.

•

Response provided to the complainant, which should include the date the response was
sent.

The quality unit must review and, as needed, investigate all written and oral complaints
involving the possible failure of a medical gas to meet any of its specifications (§§ 211.192,
211.198(a)). When an investigation is conducted, the written record must include the
investigation findings and follow-up (§ 211.198(b)(2)). These records should include the
following:
•

Date the complaint was received.

•

Action initially taken, including dates and identity of the person taking the action.

The description should facilitate investigative follow-up and identify adverse trends or patterns (e.g., a recurring
container or container closure defect).

Contains Nonbinding Recommendations
Draft — Not for Implementation

1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126

•

Follow-up action taken, including any investigation or corrective action and whether
other batches of product were potentially affected.

•

Final outcome regarding the issues raised by the complaint.
J.

Certificate of Analysis

When manufacturers use COAs to demonstrate medical gas conformance to applicable
specifications, the COAs should contain the following information:
•
•
•
•
•
•
•
•

Manufacturer name and complete address.
Supplier name and complete address (if available).
Product name (e.g., Oxygen USP).
An air liquefaction statement, as appropriate.
Lot number or other unique identification number.
Analytical results for all USP-NF monographs or other testing (e.g., impurities).
Test method used to perform the analysis.
Manufacturer or supplier signature and date.

See also section III.A.2, Quality Agreements With Suppliers.
XII.

RETURNED MEDICAL GAS

For the purposes of this guidance, FDA does not consider gas remaining in high-pressure
cylinders or cryogenic containers that are returned for refilling to be returned medical gas.
For medical gas that is returned, FDA recommends that the container be vented.
Medical gases that have been improperly stored must not be salvaged and returned to the
marketplace (§ 211.208).
XIII. ADAPTERS
For safety reasons, FDA recommends avoiding the use of adapters of any kind to circumvent the
specific medical gas valves and connections associated with a specific medical gas.
On rare occasions and only under strict control, adapters can be used to fill mixtures of medical
gases. However, manufacturers should have written procedures detailing system checks and
controls to prevent mix-ups or contamination, and to promptly identify and quarantine
compromised gases if a mix-up or contamination should occur.
XIV. GLOSSARY
The following terms are defined for the purposes of this guidance.

Contains Nonbinding Recommendations
Draft — Not for Implementation

1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171

Air separation units (ASUs): ASUs separate atmospheric air into constituent gases of oxygen,
nitrogen, and argon through a purification process of precleaning, compression, cooling, and
fractional distillation of liquefied air. ASUs are original manufacturers.
Chemical synthesizers: Chemical synthesizers or processors produce medical gas by chemical
reaction (e.g., nitrous oxide by thermal degradation of ammonium nitrate) or by reprocessing
feeder gas. Feeder gas is often the waste stream of other industrial manufacturing operations,
which is then purified and treated to manufacture a medical gas.
Cryogenic medical gas containers: Containers used to hold a low-temperature, low-pressure
liquid product. They can be divided into:
•

Cryogenic medical gas home containers: Containers designed to hold liquid oxygen at
a patient’s residence.

•

Portable medical gas cryogenic containers: Containers that are capable of being
transported and are intended to be connected to a medical gas supply system within a
hospital, health care entity, nursing home, other facility, or home health care setting, or
that are base units used to fill small cryogenic containers for use by individual patients.
The term does not include cryogenic containers that are not designed to be connected to a
medical gas supply system (e.g., tank trucks, trailers, rail cars) or small cryogenic gas
containers for use by individual patients, such as portable liquid oxygen containers, as
defined in 21 CFR 868.5655.

Designated medical gas: A drug that is manufactured or stored in a liquefied,
nonliquefied, or cryogenic state; is administered as a gas; and is identified in section 575(1) of
the FD&C Act (e.g., Oxygen USP, Carbon Dioxide USP, Nitrogen NF, Nitrous Oxide USP,
Helium USP, Medical Air USP).
Manufacturer: Any person or firm that manufactures a medical gas, which includes producing,
cascading, distributing, filling, mixing, purifying, separating, transferring, and transfilling
medical gases. This includes original manufacturers.
Original manufacturer: The original manufacturer of the medical gas, that is, the person or
entity that initially produces the gas by chemical reaction, physical separation, compression of
atmospheric air, or other means, including ASUs and chemical synthesizers or processors as well
as transfillers who manufacture medical gas by mixing other gases.
Transfillers: Transfillers manufacture medical gas by transferring the gas, either in a liquid or
gaseous state, from a larger container into smaller containers. Manufacturers who combine
different medical gases are considered both transfillers and original manufacturers.
Uninterrupted filling sequence: A single, continuous filling sequence with no breaks or
shutdowns occurring during the filling operation. This procedure uses the same personnel,
equipment, and batch of component.

File Type	application/pdf
File Title	Current Good Manufacturing Practice for Medical Gases Guidance for Industry
Subject	Current Good Manufacturing Practice for Medical Gases Guidance for Industry
Author	FDA/CDER
File Modified	2018-04-12
File Created	2017-06-26